HomeCompareZEAL vs JEPI

ZEAL vs JEPI: Dividend Comparison 2026

ZEAL yields 11.37% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZEAL wins by $13.4K in total portfolio value
10 years
ZEAL
ZEAL
● Live price
11.37%
Share price
$17.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.4K
Annual income
$2,315.19
Full ZEAL calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — ZEAL vs JEPI

📍 ZEAL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZEALJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZEAL + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZEAL pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZEAL
Annual income on $10K today (after 15% tax)
$966.46/yr
After 10yr DRIP, annual income (after tax)
$1,967.91/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, ZEAL beats the other by $668.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZEAL + JEPI for your $10,000?

ZEAL: 50%JEPI: 50%
100% JEPI50/50100% ZEAL
Portfolio after 10yr
$35.7K
Annual income
$1,921.90/yr
Blended yield
5.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ZEAL right now

ZEAL
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Price Target
$29.00
+64.9% upside vs current
Range: $26.00 — $32.00
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZEAL buys
0
JEPI buys
0
No recent congressional trades found for ZEAL or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZEALJEPI
Forward yield11.37%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$42.4K$29.0K
Annual income after 10y$2,315.19$1,528.62
Total dividends collected$17.2K$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ZEAL vs JEPI ($10,000, DRIP)

YearZEAL PortfolioZEAL Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$11,837$1,137.01$11,260$840.19+$577.00ZEAL
2$13,923$1,257.83$12,641$907.94+$1.3KZEAL
3$16,281$1,382.75$14,150$978.20+$2.1KZEAL
4$18,932$1,511.09$15,795$1,050.85+$3.1KZEAL
5$21,899$1,642.16$17,584$1,125.74+$4.3KZEAL
6$25,207$1,775.29$19,526$1,202.74+$5.7KZEAL
7$28,881$1,909.79$21,628$1,281.69+$7.3KZEAL
8$32,948$2,045.01$23,898$1,362.43+$9.1KZEAL
9$37,435$2,180.34$26,347$1,444.79+$11.1KZEAL
10$42,370$2,315.19$28,982$1,528.62+$13.4KZEAL

ZEAL vs JEPI: Complete Analysis 2026

ZEALStock

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Full ZEAL Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this ZEAL vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZEAL vs SCHDZEAL vs OZEAL vs KOZEAL vs MAINZEAL vs JEPQZEAL vs XYLDZEAL vs DIVOZEAL vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.